ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

…, M Hussain, S Oudard, JE Gschwend, P Albers… - Nature, 2021 - nature.com
Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) …

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group …

S Krege, J Beyer, R Souchon, P Albers, W Albrecht… - European urology, 2008 - Elsevier
OBJECTIVES: The first consensus report presented by the European Germ Cell Cancer
Consensus Group (EGCCCG) in the year 2004 has found widespread approval by many …

Guidelines on testicular cancer: 2015 update

P Albers, W Albrecht, F Algaba, C Bokemeyer… - European urology, 2015 - Elsevier
… Financial disclosures: Peter Albers certifies that all conflicts of interest, including specific … ,
or pending), are the following: Peter Albers has received consultancy fees from Thieme Books, …

Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial

…, D Flieger, S Renoth, S Weineck, P Albers… - Cancer Immunology …, 2002 - Springer
In this study we have presented in vitro data and results of a preliminary clinical trial using
dendritic cells (DC) in patients with progressive metastatic renal cell carcinoma. DC precursor …

EAU guidelines on testicular cancer: 2011 update

P Albers, W Albrecht, F Algaba, C Bokemeyer… - European urology, 2011 - Elsevier
… Author contributions: Peter Albers had full access to all the data in the study and takes …
, or pending), are the following: Peter Albers receives royalties from Thieme Books. He is a …

Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant …

P Albers, R Siener, S Krege, HU Schmelz… - Journal of Clinical …, 2008 - ascopubs.org
Purpose Retroperitoneal lymph node dissection (RPLND) and adjuvant chemotherapy are
two adjuvant treatment options for patients with clinical stage I nonseminomatous germ cell …

Testicular cancer

L Cheng, P Albers, DM Berney, DR Feldman… - Nature Reviews …, 2018 - nature.com
Testicular cancer is the most common malignancy among men between 14 and 44 years of
age, and its incidence has risen over the past two decades in Western countries. Both …

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an …

CN Sternberg, I Skoneczna, JM Kerst, P Albers… - The lancet …, 2015 - thelancet.com
Background Patients with muscle-invasive urothelial carcinoma of the bladder have poor
survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus deferred …

Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial

…, A Albers, J Löffel, A Neubauer, P Albers… - Human gene …, 2001 - liebertpub.com
Therapeutic vaccination of tumor patients with cytokine gene-transfected tumor cells leads
to tumor regression in animal models but has so far not resulted in significant clinical benefit. …

Poisoning and deactivation of palladium catalysts

P Albers, J Pietsch, SF Parker - Journal of Molecular Catalysis A: Chemical, 2001 - Elsevier
Some of the major causes for deactivation and premature degradation of palladium catalysts
are briefly summarised. These include particle growth for various reasons, coke deposition …